Mankind Pharma Ltd (MANKIND) — shareholding pattern, promoter holding, financials and share price
About Mankind Pharma Ltd (MANKIND)
Mankind Pharma Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as MANKIND and on the BSE under scrip code 543904. Its ISIN is INE634S01028.
Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products. [1]
Mankind Pharma Limited is a leading Indian pharmaceutical company engaged in manufacturing and marketing a broad spectrum of pharmaceutical products and healthcare solutions. The company operates in both acute and chronic therapeutic areas, with a notable presence in cardiovascular, anti-diabetic, and neuro/CNS segments.
In Q3 FY26, Mankind Pharma reported a revenue increase of 11.5% YoY, driven by strong domestic pharmaceutical performance. Adjusted EBITDA margins improved to 25.9%, showcasing robust operational efficiency.
Listed peers in Pharmaceuticals: Cipla Ltd, Zydus Lifesciences Ltd, Lupin Ltd, Dr Reddys Laboratories Ltd, Aurobindo Pharma Ltd, Laurus Labs Ltd.
Valuation & Returns
10 Jul 2026At ₹2,526.55 a share on 10 Jul 2026, Mankind Pharma Ltd (MANKIND) was valued at a price-to-earnings ratio of 53.84x against an industry P/E of 36.41x and a price-to-book of 7.28x on a book value of ₹347.03 per share as of Mar 2025. Solomo computes return on equity of 13.52% and return on capital employed of 13.01% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 53.84x
- Industry P/E
- 36.41x
- P/B
- 7.28x
- EPS (TTM)
- ₹46.93
- Book value / share
- ₹347.03
- ROE
- 13.52%
- ROCE
- 13.01%
- ROA
- 6.98%
- Debt / equity
- 0.59x
- Dividend yield
- 0.04%
- EBITDA margin
- 27.02%
- 52-week range
- ₹1,909.9 – ₹2,726.75
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Mankind Pharma Ltd (MANKIND) reported revenue of ₹14,278 crore, net profit of ₹1,938 crore and earnings per share of ₹46.34. That compares with revenue of ₹12,207 crore and net profit of ₹2,011 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹3,443 crore and net profit ₹559 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 7,782 | 8,749 | 10,260 | 12,207 | 14,278 |
| Net profit (₹ cr) | 1,453 | 1,310 | 1,942 | 2,011 | 1,938 |
| EPS (₹) | 35.78 | 32 | 47.75 | 48.26 | 46.34 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 14.65% | 8.26% | 18.98% |
| Profit growth | 14.48% | 10.69% | 3.57% |
| Stock price CAGR | - | 11% | -3% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 72.63% of Mankind Pharma Ltd (MANKIND) (down 0.03 pp QoQ), foreign institutional investors (FII) hold 9.45% and domestic institutional investors (DII) hold 15.39%. Market capitalisation was ₹1,04,346 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Jun 2023.
Largest disclosed public shareholders in Jun 2026: NPS TRUST - A/C SBI PENSION FUND SCHEME - CORPORAT 2.77%, NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA NIF 2.07%, SBI ARBITRAGE OPPORTUNITIES FUND 1.56%, GOVERNMENT PENSION FUND GLOBAL 1.29%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 72.63% | - | 9.45% | 15.39% | 27.37% |
| Mar 2026 | 72.66% | - | 10.24% | 14.46% | 27.34% |
| Dec 2025 | 72.66% | - | 11.34% | 13.25% | 27.34% |
| Sep 2025 | 72.67% | - | 12.84% | 11.92% | 27.33% |
| Jun 2025 | 72.68% | - | 13.07% | 11.5% | 27.32% |
| Mar 2025 | 72.7% | - | 12.92% | 11.48% | 27.3% |
| Dec 2024 | 72.71% | - | 13.34% | 11.06% | 27.29% |
| Sep 2024 | 74.87% | - | 12.37% | 9.9% | 25.13% |